These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 22734476)
1. Long-term potency preservation following brachytherapy for prostate cancer. Roach M BJU Int; 2012 Jul; 110(2):225. PubMed ID: 22734476 [No Abstract] [Full Text] [Related]
2. Long-term potency preservation following brachytherapy for prostate cancer. Snyder KM; Stock RG; Buckstein M; Stone NN BJU Int; 2012 Jul; 110(2):221-5. PubMed ID: 22734475 [TBL] [Abstract][Full Text] [Related]
3. Erectile function durability following permanent prostate brachytherapy. Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Kurko BS; Anderson R; Lief JH Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):639-48. PubMed ID: 19303721 [TBL] [Abstract][Full Text] [Related]
4. Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. Pahlajani G; Raina R; Jones JS; Burdick M; Ali M; Li J; Mahadevan A; Ciezki J; Zippe C BJU Int; 2010 Nov; 106(10):1524-7. PubMed ID: 20477827 [TBL] [Abstract][Full Text] [Related]
6. The dosimetry of brachytherapy-induced erectile dysfunction. Merrick GS; Butler WM Med Dosim; 2003; 28(4):271-4. PubMed ID: 14684193 [TBL] [Abstract][Full Text] [Related]
7. The concept of erectile function preservation (penile rehabilitation) in the patient after brachytherapy for prostate cancer. Stember DS; Mulhall JP Brachytherapy; 2012; 11(2):87-96. PubMed ID: 22330103 [TBL] [Abstract][Full Text] [Related]
8. Erectile function after prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Kurko BS; Lief JH; Allen ZA Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):437-47. PubMed ID: 15890585 [TBL] [Abstract][Full Text] [Related]
9. A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy. Matsushima M; Kikuchi E; Maeda T; Nakashima J; Sugawara A; Ando T; Mizuno R; Nagata H; Miyajima A; Shigematsu N; Oya M J Urol; 2013 Mar; 189(3):1014-8. PubMed ID: 23017516 [TBL] [Abstract][Full Text] [Related]
10. Cancer therapies touted in physician, hospital, web advertising. Newman L J Natl Cancer Inst; 2000 Jun; 92(12):965. PubMed ID: 10861305 [No Abstract] [Full Text] [Related]
11. Nursing assessment of sexual function following permanent prostate brachytherapy for patients with early-stage prostate cancer. Stipetich RL; Abel LJ; Blatt HJ; Galbreath RW; Lief JH; Butler WM; Merrick GS Clin J Oncol Nurs; 2002; 6(5):271-4. PubMed ID: 12240487 [TBL] [Abstract][Full Text] [Related]
13. How to preserve potency and continence in localized prostate cancer. Breda G; Celia A BJU Int; 2007 Jul; 100 Suppl 2():29-31. PubMed ID: 17594355 [No Abstract] [Full Text] [Related]
14. [Sexual dysfunction after curietherapy and external radiotherapy of the prostate for localized prostate cancer]. Huyghe E; Bachaud JM; Achard JL; Bossi A; Droupy S; Prog Urol; 2009 Dec; 19 Suppl 4():S173-6. PubMed ID: 20123514 [TBL] [Abstract][Full Text] [Related]
15. Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I(125) implant brachytherapy for prostate cancer. A longitudinal study of a single-institution. Morgia G; Castelli T; Privitera S; Al-Nakib C; Favilla V; Marchese F; Cimino S; Russo GI Aging Male; 2016; 19(1):15-9. PubMed ID: 26376010 [TBL] [Abstract][Full Text] [Related]
16. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. Stock RG; Kao J; Stone NN J Urol; 2001 Feb; 165(2):436-9. PubMed ID: 11176391 [TBL] [Abstract][Full Text] [Related]
17. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer. Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568 [TBL] [Abstract][Full Text] [Related]
18. Lovastatin may reduce the risk of erectile dysfunction following radiation therapy for prostate cancer. Anscher MS; Chang MG; Moghanaki D; Rosu M; Mikkelsen RB; Holdford D; Skinner V; Grob BM; Sanyal A; Wang A; Mukhopadhyay ND Acta Oncol; 2016 Dec; 55(12):1500-1502. PubMed ID: 27582017 [No Abstract] [Full Text] [Related]
19. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948 [TBL] [Abstract][Full Text] [Related]
20. Open to debate. The motion: Radiotherapy for prostate cancer preserves sexual function to a greater extent than nerve sparing radical prostatectomy. Pinkawa M; Gontero P Eur Urol; 2009 Jul; 56(1):212-4. PubMed ID: 19395152 [No Abstract] [Full Text] [Related] [Next] [New Search]